Toxicity Profile of Panobinostat as seen in the PANORAMA Trial

Andrzej Jakubowiak, MD, PhD
Published Online: August 22, 2014
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Clinical Pearls:
  • In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm.
  • A higher rate of thrombocytopenia and other hematological toxicities were also seen in the panobinostat arm.
  • However, all of the toxicities were mostly manageable and did not impact the outcome of the trial.
  • More details are needed to get a better understanding of the toxicity profile of this combination in this setting.


Related Articles
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 5-2 against the accelerated approval of panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms.
The FDA has approved bortezomib (Velcade) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) as a frontline treatment for patients with mantle cell lymphoma.
The FDA has scheduled an ODAC advisory hearing to discuss the NDA for panobinostat in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
JTT Articles
CD19-Targeted Agents Continue to Show Positive Outcomes
HPV Test With Genotyping Supplants Pap Test
Bromodomain Inhibitor Shows Activity in Hematologic Malignancies
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.